Authors: Liubao, Peng¹; Xiaomin, Wan¹; Chongqing, Tan¹; Karnon, Jon²; Gannong, Chen³; Jianhe, Li¹; Wei, Cui¹; Xia, Luo¹; Junhua, Cao¹

Source: PharmacoEconomics, Volume 27, Number 10, 1 October 2009 , pp. 873-886(14)

Publisher: Adis International

Abstract:

Background An oncology trial compared four cycles of doxorubicin/cyclophosphamide (AC) with four cycles of docetaxel/cyclophosphamide (TC) in operable breast cancer patients (71% were diagnosed with hormone receptor positive and 48% with node-negative breast cancer). The objective of this study was to estimate the lifetime cost effectiveness of AC versus TC, from a Chinese healthcare provider perspective, based on a clinical trial.

Methods A lifetime cost-effectiveness analysis was performed using a Markov model. Events rates and utilities in the Markov model were derived from published papers. Data on cost of breast cancer care were obtained from the Second Xiangya Hospital of Central South University, Changsha, PR China. One-way sensitivity analysis and probabilistic sensitivity analysis were undertaken. Cost estimates were valued in Chinese yuan (Y), year 2008 values. All costs and outcomes were discounted at 3% per annum.

Results Patients receiving TC gained 14.45 QALYs, 0.41 QALYs more than patients receiving AC. The lifetime costs of patients receiving TC were Y93 511, Y10 116 more than that of AC patients. The incremental cost-effectiveness ratios were Y26 742 per life-year gained (£2719.8 per year) and Y24 305 per QALY gained (£2471.9 per QALY). The most sensitive parameter in the model was the cost of primary cancer treatments in the TC arm. At a threshold willingness to pay of Y86 514 per QALY, the probability of TC being cost effective was 90%.

Conclusions Our model suggests that TC may be considered cost effective from a Chinese healthcare provider perspective, according to the threshold defined by the WHO.

Document Type: Research article

Affiliations: 1: 1 Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China 2: 2 Department of Public Health, University of Adelaide, Adelaide, South Australia, Australia 3: 3 Department of Mammary Gland and Thyroid Gland of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, PR China

Publication date: 2009-10-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Liubao, Peng ;  Xiaomin, Wan ;  Chongqing, Tan ;  Karnon, Jon ;  Gannong, Chen ;  Jianhe, Li ;  Wei, Cui ;  Xia, Luo ;  Junhua, Cao

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers